Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells for AML Consolidation
NCT05334693Phase 2Recruiting
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Start
- Nov 2021
- Primary completion
- Dec 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of expanded haploidentical NK cells in acute myeloid leukemia (AML), sponsored by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology. Primary endpoints: Relapse-free survival at 2 years and Overall survival at 2 years. Started Nov 2021; status: recruiting.
02
Drugs
expanded haploidentical NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05334693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334693.